Increased glucocorticoid activity in men with cardiovascular risk factors

Hypertension
B R WalkerG C Watt

Abstract

The association between hypertension and insulin resistance might be explained by increased activity of the principal glucocorticoid, cortisol. Recent data show that the intensity of dermal vasoconstriction after topical application of glucocorticoids is increased in patients with essential hypertension. In this report, we examine whether increased glucocorticoid sensitivity or secretion is associated with insulin resistance and is a cause or consequence of hypertension. We studied 32 men (aged 47 to 56 years) from a cross-sectional study and 105 men (aged 23 to 33 years) in whom predisposition to high blood pressure has been defined by their own blood pressure and the blood pressures of their parents. In both populations, increased dermal glucocorticoid sensitivity was associated with relative hypertension, insulin resistance, and hyperglycemia. In young men with higher blood pressure whose parents also had high blood pressure, enhanced glucocorticoid sensitivity was accompanied by enhanced secretion of cortisol, enhanced ligand-binding affinities for dexamethasone in leukocytes, and impaired conversion of cortisol to inactive metabolites (cortisone and 5beta-dihydrocortisol). Increased tissue sensitivity to cortisol, amplifie...Continue Reading

References

Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·U SträhleG Schütz
Aug 1, 1992·Metabolism: Clinical and Experimental·P MårinP Björntorp
Aug 22, 1987·Lancet·G M Reaven, B B Hoffman
Aug 1, 1986·Endocrine Reviews·R M SapolskyB S McEwen
Dec 1, 1985·The Journal of Clinical Endocrinology and Metabolism·R C GaillardJ H Saurat
Feb 1, 1974·The Journal of Clinical Endocrinology and Metabolism·B ZumoffL Hellman
May 2, 1981·British Medical Journal·J CarmichaelI W Grant
May 1, 1982·The Journal of Clinical Endocrinology and Metabolism·R MarksJ W Funder
Jun 1, 1995·Clinical Science·S B HarrapG C Watt
Feb 1, 1994·Diabetologia·D I PhillipsC Osmond
Oct 1, 1993·Frontiers in Neuroendocrinology·M F DallmanM Smith
Apr 1, 1993·The Journal of Steroid Biochemistry and Molecular Biology·C J KenyonR Fraser
Nov 1, 1995·International Journal of Microcirculation, Clinical and Experimental·H SuzukiG W Schmid-Schönbein
Jun 1, 1996·Endocrine Reviews·R Groote Veldman, A E Meinders

❮ Previous
Next ❯

Citations

Jan 7, 2010·European Journal of Applied Physiology·Cora Stefanie WeberHans C Deter
Mar 29, 2001·Current Hypertension Reports·M S Golub
Mar 26, 2003·Journal of Psychiatric Research·Nick J CouplandJessica Myrholm
Feb 5, 2004·Social Science & Medicine·Sabine R Kunz-EbrechtAndrew Steptoe
Jan 3, 2003·Psychoneuroendocrinology·M BartelsE J C de Geus
Aug 5, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·M al'Absi, D K Arnett
May 2, 2002·The Journal of Steroid Biochemistry and Molecular Biology·Guthrie BlackhurstJohn M C Connell
Apr 18, 2001·Trends in Endocrinology and Metabolism : TEM·R C WilsonM I New
May 14, 1999·Trends in Endocrinology and Metabolism : TEM·M DodicM Wintour
Mar 1, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tomoatsu MuneKohei Kaku
Oct 8, 2008·International Journal of Obesity : Journal of the International Association for the Study of Obesity·R PasqualiU Pagotto
Jan 25, 2003·Diabetes, Obesity & Metabolism·Rebecca M Reynolds, Brian R Walker
Apr 12, 2000·Kidney International·P Ferrari, Z Krozowski
Jul 18, 2001·Current Opinion in Nephrology and Hypertension·D B Corry, M L Tuck
Nov 26, 2009·Psychosomatic Medicine·Stephen B ManuckMatthew F Muldoon
Dec 11, 2007·Clinical and Experimental Pharmacology & Physiology·Maria A Matuszek, Stephen H Boutcher
Feb 22, 2012·PloS One·Raymond NoordamUNKNOWN Leiden Longevity Study group
Nov 7, 2007·European Journal of Endocrinology·Brian R Walker
Feb 24, 2007·Vascular Health and Risk Management·Judith A WhitworthJohn J Kelly
Mar 24, 2006·Psychosomatic Medicine·Mustafa al'AbsiLorentz Wittmers
Sep 19, 2008·Psychosomatic Medicine·Gerard J MolloyAndrew Steptoe
Mar 5, 2005·European Journal of Endocrinology·Rebecca M ReynoldsDavid I W Phillips
Mar 15, 2005·Journal of Endocrinological Investigation·P PutignanoF Cavagnini
Feb 11, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ankur JainAbbot F Clark
Nov 10, 2001·Trends in Endocrinology and Metabolism : TEM·T C Sandeep, B R Walker
Feb 13, 2003·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Mustafa al'Absi, Lorentz E Wittmers
Apr 28, 2007·The International Journal of Neuroscience·Hernán PérezMartin Gotteland
Dec 4, 2003·Expert Opinion on Therapeutic Targets·Brian R Walker, Jonathan R Seckl
Mar 28, 2008·Expert Opinion on Investigational Drugs·Katherine A HughesBrian R Walker
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Kenji Oki, Kiminori Yamane
Oct 22, 2010·Molecular Genetics and Metabolism·Jamie W PowersEdward R B McCabe
Feb 23, 2010·The Journal of Steroid Biochemistry and Molecular Biology·Adam J RoseStephan Herzig
Apr 15, 2008·The Journal of Steroid Biochemistry and Molecular Biology·Renato Pasquali, Valentina Vicennati
Jul 13, 2007·Molecular and Cellular Endocrinology·Alexandros Vegiopoulos, Stephan Herzig
May 12, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Xiangdong SuBarry V L Potter
Feb 27, 2007·International Journal of Hygiene and Environmental Health·Lisbeth E Knudsen, Ase M Hansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.